NICE says why eye to Ozdurex and Eylea for DME
This article was originally published in Scrip
Executive Summary
In two separate pieces of final and binding guidance, NICE has recommended Bayer's Eylea (aflibercept) and Allergan's Ozurdex (dexamethasone intravitreal implant) for treating NHS patients with diabetic macular edema. Both sets of recommendations come with restrictions: Eylea can be used if the eye has a central retinal thickness of 400 micrometres or more at the start of treatment, and if Bayer provides the drug at a discount as agreed in a confidential patient access scheme. Meanwhile, Ozurdex is to be used in patients if the implant is to be used in an eye with an intraocular (pseudophakic) lens and if non-corticosteroid treatment is unsuitable or ineffective. Both drugs will compete against Roche's Lucentis (ranibizumab) and off-label Avastin. NICE first put its guidance out for consultation in February.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.